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in the DNA-binding homeodomain. Computer modeling 
predicted that the T194R change would alter the homeodo-
main structure. The T194R protein did not bind tested LHX3 
DNA recognition sites and did not activate the   -glycoprotein 
and  PRL target genes.  Conclusion: The T194R mutation af-
fects a critical residue in the LHX3 protein. This study extends 
our understanding of the phenotypic features, molecular 
mechanism, and developmental course associated with mu-
tations in the  LHX3  gene. 
 
Copyright © 2012 S. Karger AG, Basel 
 Introduction 
 Development of the hormone-secreting cells of the hu-
man anterior pituitary gland requires the coordinated ac-
tions of regulatory genes that encode signaling pathway 
components and transcription factors leading to the sub-
sequent expression of specialized genes that establish the 
differentiated character of the cells  [1–4] . Within these 
regulatory genes, inherited and de novo mutations in 
those encoding transcription factors have been associat-
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 Abstract 
 Background/Aims:  Recessive mutations in the  LHX3 ho-
meodomain transcription factor gene are associated with 
developmental disorders affecting the pituitary and ner-
vous system. We describe pediatric patients with combined 
pituitary hormone deficiency (CPHD) who harbor a novel 
mutation in  LHX3 .  Methods:  Two female siblings from relat-
ed parents were examined. Both patients had neonatal com-
plications. The index patient had CPHD featuring deficien-
cies of GH, LH, FSH, PRL, and TSH, with later onset of ACTH 
deficiency. She also had a hypoplastic anterior pituitary, re-
spiratory distress, hearing impairment, and limited neck ro-
tation. The  LHX3 gene was sequenced and the biochemical 
properties of the predicted altered proteins were character-
ized.  Results: A novel homozygous mutation predicted to 
change amino acid 194 from threonine to arginine (T194R) 
was detected in both patients. This amino acid is conserved 
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ed with pediatric diseases including both isolated hor-
mone deficiencies and combined pituitary hormone de-
ficiency (CPHD) diseases. Critical pituitary transcription 
factors include the HESX1, ISL1, LHX3, LHX4, PAX6, 
PIT-1 ( POU1F1  gene), OTX1, PITX1, PITX2, PROP1, 
SIX3, and SIX6 proteins that possess structurally related 
homeodomain tertiary structures that interact with tar-
get  cis DNA elements in the promoters and enhancers of 
pituitary genes  [1–4] .
 LHX3 is a member of the LIM-homeodomain (LIM-
HD) subfamily of transcription factor proteins that are 
characterized by two amino terminal LIM domains (cys-
teine-rich structures that are important for protein-pro-
tein interactions) and a centrally-located DNA-binding 
homeodomain  [5] . Biochemical studies have shown that 
LHX3 can activate pituitary genes encoding transcrip-
tion factors, hypothalamic signal receptors, and hor-
mones [e.g.  5–7 ], placing the  LHX3 gene in an early regu-
latory position involved in the determination and differ-
entiation of all five pituitary cell types [reviewed in  4 ]. 
During embryogenesis, the LHX3  gene is expressed in the 
embryonic brain, spinal cord and Rathke’s pouch, an ear-
ly structure in pituitary development; expression is also 
detectable in the adult pituitary gland  [5, 8–10] . Mice with 
inactive  Lhx3 genes die shortly following birth of pre-
sumptive nervous system deficiencies and have poor 
structural pituitary development with an associated ab-
sence of four of the differentiated cell types and only a 
minimal population of ACTH-producing corticotropes 
 [11] . By contrast, mice lacking only the carboxyl terminus 
of the protein are viable but have anterior pituitary defi-
cits causing dwarfism, female infertility, and thyroid in-
sufficiency  [12] .
 Patients who are homozygous for the known rare, re-
cessive mutations in the  LHX3 gene have CPHD with de-
ficiencies in GH, PRL, TSH, LH, and FSH. Other syn-
dromic symptoms associated with these patients can
include normal, hypoplastic, or enlarged anterior pitui-
taries, a rigid spine with limited neck rotation, hearing 
loss, and ACTH deficiency  [13–18] . The endocrine defi-
cits associated with CPHD can result in short stature, 
metabolic defects, failure of puberty, and other symp-
toms resulting from pituitary gland inaction. There ap-
pears to be a structure/function relationship between the 
predicted changes that the observed mutations cause, and 
the resulting disease. Mutations that compromise the 
overall function of the gene or protein and mutations af-
fecting the LIM domains or the homeodomain appear to 
result in syndromes involving both the endocrine (CPHD) 
and nervous (limited neck rotation, possible deafness) 
systems. By contrast, the carboxyl terminus of LHX3 pro-
teins appears to have roles that are limited to pituitary 
development and function: mutations affecting only this 
domain in both human patients and engineered animal 
models are associated with pituitary diseases without any 
apparent nervous system deficits  [12, 17] .
 In this study, we describe CPHD patients with a syn-
drome including GH, LH, FSH, PRL, and TSH deficiency, 
evolving onset of ACTH deficiency, hypoplastic anterior 
pituitary morphology, respiratory distress, hearing im-
pairment, and limited neck rotation. These patients har-
bor a novel  LHX3 mutation that causes substitution of
a conserved, critical amino acid in the homeodomain 
(T194R) that abrogates DNA-binding and pituitary gene 
activation in molecular analyses.
 Patients and Methods 
 Patients 
 Two female siblings were examined at the University Chil-
dren’s Hospital in Munich, Germany. Both developed respiratory 
distress combined with hypoglycemia shortly after birth. The 
first child of the family (patient IV2,  fig. 1 a) was born full term at 
41 + 1 weeks to a 29-year-old mother originating from India. The 
family reported that there is a common connection four or five 
generations back ( fig. 1 a). She was delivered by caesarean section 
for breech presentation and pathological cardiotocography. Ap-
gar was 8/9/10, umbilical cord pH was 7.35. Birth weight and 
length corresponded to the 3rd percentile ( table 1 ). At the age of 
20 h, she started to breathe irregularly, and a cardiopulmonary 
resuscitation was necessary 1 h later. After intubation, a low blood 
glucose was present. Neonatal screening (i.e. detection of more 
than 30 inborn errors of metabolism, TSH, 17-hydroxyprogester-
one) was normal; however, TSH levels were retrospectively not 
detectable. On echocardiography she had a large patent ductus 
artery and small atrial septal defect. She developed a severe edema 
of the brain, recurrent seizures, and no spontaneous movements. 
She died at the age of 20 days of cardiorespiratory insufficiency. 
With consent, fibroblasts were preserved, and genomic DNA was 
later extracted.
 The index patient (patient IV4,  fig. 1 a) was a full-term infant 
of 37 + 1 weeks, born by caesarean section due to premature la-
bor. By that time, her mother was 32 years old (G3P3). At birth, 
her Apgar was 9/8/9, umbilical cord was pH 7.29, and weight was 
2,501 g (9th percentile). Postnatally, patient IV4 showed signs of 
respiratory distress. After 48 h, an intubation was required. A 
chest X-ray revealed bilateral alveolar infiltrates, a grade 3 respi-
ratory distress syndrome. Surfactant was administrated to the pa-
tient, and she began to improve. Four days later, she was extu-
bated without any difficulties. After 3 more days, no further arti-
ficial respiration was required. Her examination showed a large 
anterior and posterior fontanel, prominent eyes, short neck, rigid 
spine, failure to thrive, sucking weakness, hypoglycemia, and 
neonatal jaundice. She was completely tube fed until the 9th day 
of life. Afterwards, additional tube feeding was still necessary due 
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to sucking weakness. She developed recurrent hypoglycemia 
without symptoms despite nutritional supplements such as malto-
dextrin. The overall weight gain was poor.
 Endocrine diagnostics of patient IV4 on day 3 showed a TSH 
below the detection limit consistent with central hypothyroidism 
( table 1 ), thyroxin levels were also low (0.005 nmol/l), therefore 
thyroid replacement was started on day 5 of life. Further tests of 
the hypothalamic-pituitary axis were performed on day 14 and 
revealed GH ( ! 0.1 ng/ml), IGF-I ( ! 25   g/l), PRL (17.5 nmol/l), 
LH ( ! 0.1 mU/ml) and FSH (0.2 mU/ml) deficiencies together with 
a cortisol (0.075–0.44   mol/l) in the low normal range ( table 1 ). 
ACTH levels were within normal limits. She was started on GH 
treatment on day 17. At the age of 4 months, LH and FSH were re-
evaluated and showed the same results as in the newborn age. At 
a
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b c d e
 Fig. 1. DNA analysis reveals a homozygous mutation in the  LHX3 
gene in patients with CPHD.  a Pedigree of the affected family. 
Filled symbols indicate patients with homozygous genotype. 
Half-filled symbols denote heterozygous individuals. A line 
through a symbol indicates that the subject is deceased. The dot-
ted line indicates a family connection four or five generations 
back from the index patient (IV4).  b A 3-Tesla MRI of patient IV4 
reveals an absent or severely hypoplastic anterior pituitary gland. 
The anterior part of the sella is filled with a cystic structure with 
high signal intensity in non-enhanced T 1 -weighted sequence 
(open arrow) and a reduced signal intensity in T 2 -weighted se-
quences (not shown), most likely corresponding to a cyst with 
high protein content. The posterior pituitary gland is found in an 
orthotopic location (arrow).  c Coronal view.  d ,  e A T 2 -weighted 
sequence of the cervical spine demonstrates a reduced cervical 
lordosis with slight kyphosis of the vertebral bodies in segment C2 
to C5.  f–h DNA sequencing reveals a C to G mutation in the  LHX3 
gene altering a threonine (Thr) to an arginine (Arg) ( f control; 
 g III4 (mother of patient IV4 with heterozygous genotype);  h pa-
tient IV4).  
C
o
lo
r v
er
si
o
n 
av
ai
la
b
le
 o
n
lin
e
 Bechtold-Dalla Pozza  /Hiedl  /Roeb  /
Lohse  /Malik  /Park  /Durán-Prado  /Rhodes  
 Horm Res Paediatr 2012;77:41–51 44
the age of 1 year, the patient developed an addisonian crisis, and 
detected ACTH levels were low by that time (1.32 pmol/l) as well 
as cortisol ( ! 0.006   mol/l).
 A recent brain MRI at the age of 1.5 years revealed the presence 
of an absent or severely hypoplastic anterior pituitary and ortho-
topic posterior pituitary that may be enlarged with a lipoid cyst 
( fig. 1 b). MRI of the cervical spine showed normal alignment and 
configuration of the cervical spine without any apparent struc-
tural abnormalities with a loss of cervical lordosis. In addition, 
there was impaired cervical rotation limiting movement of the pa-
tient’s neck to approximately 35° to each side. A brainstem-evoked 
response audiometry test was negative for both ears. Hearing im-
pairment was confirmed recently at the age of 1.5 years.
 DNA Analysis 
 The array of hormone deficiencies and the associated im-
paired cervical rotation suggested that patient IV4 may have a 
mutation in the  LHX3 transcription factor gene. After obtaining 
informed consent, blood samples were collected, including also 
from first-degree relatives whenever possible. The seven exons of 
 LHX3 were amplified by PCR and sequenced with the ABI PRISM 
Big Dye Terminator v3.1 Ready Reaction Cycle Sequencing kit 
(Applied Biosystems, Foster City, Calif., USA). Electrophoresis 
was performed on an ABI PRISM 3130 Genetic Analyzer (Applied 
Biosystems).
 Plasmid Construction and in vitro Transcription/Translation 
 Human LHX3 cDNA expression plasmids have been de-
scribed  [7, 19] . The T194R mutation was introduced using the 
QuikChange  kit (Stratagene/Agilent, La Jolla, Calif., USA) with 
the following oligonucleotide primers: 5  -agctctcgtccgagagggg-
cctgg-3  , 5  -ccaggcccctctcggacgagagct-3  . Radiolabeled wild-type 
(WT) and mutant proteins were synthesized in vitro from tran-
scribed cDNAs using TNT rabbit reticulocyte lysate reagents 
(Promega, Madison, Wisc., USA) and  35 S-methionine as de-
scribed  [20] . Proteins were analyzed by electrophoresis in 12% 
acrylamide gels followed by fluorography as described  [21] . Dried 
gels were imaged with a Storm phosphorimager (Amersham Bio-
sciences, Piscataway, N.J., USA) or BioMax MR X-ray film (Ko-
dak, Rochester, N.Y., USA).
 Homology Structural Modeling 
 Homology structural modeling of the LHX3 homeodomain 
was performed following methodology described previously  [21] . 
Briefly, the LHX3 homeodomain amino acid sequence was 
screened against the PDB database using BLAST-p. Among all the 
possible templates, the 1HDD file corresponding to an engrailed 
homeodomain DNA complex at 2.8 Å resolution  [22] was selected 
as the best suitable (BLAST score 1e –8 ) displaying homology high-
er than 50% (46% identity). The raw LHX3 homeodomain se-
quence was structurally aligned to the 1HDD, subjected to energy 
minimization and evaluated with ANOLEA, as described  [21] . 
The accepted model of each homeodomain was docked into the 
DNA structure of the 1HDD protein-DNA complex structure. 
The T194 residue of the LHX3 model was changed to arginine (R). 
All the rotamers for this residue were tested to find putative con-
tacts with other amino acids in the homeodomain structure. The 
resultant 3D PDB files were exported to pov format and rendered 
using PovRay 3.62 to obtain high-quality pictures.
 Electrophoretic Mobility Shift Analysis 
 Electrophoretic mobility shift assays (EMSA) were performed 
using radiolabeled DNA probes representing the pituitary glyco-
protein basal element of the   -glycoprotein subunit (  GSU) gene 
promoter or the LHX3 consensus-binding site as described  [23] . 
Proteins for EMSA were generated by in vitro translation as de-
scribed above except that cold amino acids were substituted for 
 35 S-methionine. Results were visualized by autoradiography or 
using a phosphorimager.
 Luciferase Assays 
 Mouse pituitary GHFT1 cells were a gift from Dr. Pamela Mel-
lon (University of California, San Diego, Calif., USA). GHFT1 
cells were cultured and transfected as described  [20] . Luciferase 
activity was measured 48 h after transfection  [20, 24] . All assay 
points were performed in triplicate. Total cell protein was deter-
mined by the Bradford method (BioRad, Hercules, Calif., USA), 
and luciferase activity was normalized to protein concentration.
 Results 
 Patient Gene Analysis 
 Genomic sequencing of patients IV2 and IV4 revealed 
a homozygous C ] G transversion mutation in the fourth 
coding exon of the  LHX3 gene ( fig. 1 a, h). The clinically 
Table 1. C linical data for patients with the T194R LHX3 mutation at newborn age
Patient Gestational
age
weeks
Birth 
length
cm (SD)
Birth weight
g (SD)
Age at
manifes-
tation, h
Basal PRL
nmol/l
[44–213]
Basal TSH* 
U/ml
[0.7–15.2]
Basal GH 
ng/ml
[>7]
Basal cortisol 
mol/l
[0.14–0.55]
Basal ACTH 
pmol/ml
[2.2–11]
Basal LH 
mU/ml
[0.1–7.7]
Basal FSH 
mU/ml
[0.1–13]
IV2 41+1 48 (–1.7) 2,800 (–2.0) 20 N/A 0 N/A N/A N/A N/A N/A
IV4 37+1 45 (–2.1) 2,501 (–1.7) 48 17.5 0 <0.1 0.075 7.68 <0.1 0.2
A ge-adjusted normative data are in square brackets.
SD = Standard deviation (according to the normative Swiss data of Prader et al. [33]); N/A = not available.
* TSH levels from neonatal screening.
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unaffected parents (III4 and III5), a brother (IV3), an 
aunt (mother’s sister, III2) and a first cousin (IV1) were 
heterozygous for the mutation ( fig. 1 a, g).
 The Mutation Causes Alteration of a Conserved 
Amino Acid in the Homeodomain 
 The detected mutation changes a threonine amino acid 
at position 194 (T194) of the LHX3a protein to an arginine 
residue, a non-conservative biochemical substitution 
(T194R). The threonine at position 194 is located in the 
homeodomain which mediates LHX3 transcription factor 
interactions with target DNA sequences ( fig.  2 a). This 
threonine is entirely conserved in LHX3/LIM3 proteins 
in mammals, birds, amphibians, fish, and insects ( fig. 2 b). 
Further, the equivalent position is also a threonine in each 
of the human LIM-HD transcription factor proteins 
( fig. 2 c), suggesting that it plays a critical role in the home-
odomain of this class of developmental regulators. In vi-
tro transcription/translation of radiolabeled WT and 
T194R human LHX3a proteins produced full-length pro-
tein products that migrated in electrophoresis in accord 
with their predicted molecular sizes ( fig. 2 d).
 In order to explore the possible effect of the mutation-
caused amino acid substitution in the LHX3 homeodo-
a
b
c
d
 Fig. 2. A point mutation in the  LHX3 gene 
causes a T194R amino acid substitution in 
the homeodomain.  a Diagram of the key
domains of the 397-amino-acid human 
LHX3a protein. N-terminus = Amino ter-
minus; C-terminus = carboxyl terminus. 
 b Sequence analyses demonstrate that 
T194 is conserved in LHX3/LIM3 pro-
teins. Alignments of the homeodomain 
primary amino acid sequence are shown. 
Dashes denote gaps introduced to opti-
mize alignments; dots denote amino acid 
identity at that position; the box shows
the equivalent amino acids for T194. 
Comparisons are of human (HsLHX3) to 
chimpanzee (PtLHX3), rhesus macaque 
(MmLHX3), rat (RnLHX3), dog (CfLHX3), 
mouse (MuLHX3), pig (SsLHX3), cow 
(BtLHX3), opossum (DmLHX3), chicken 
(GgLIM3),  Xenopus laevis (XlLIM3), 
 Xenopus tropicalis (XtLIM3), zebra-
fish (DrLIM3),  Drosophila melanogaster 
(DmLIM3), and the patient.  c The threo-
nine at position 194 in LHX3 is conserved 
in human LIM-HD class transcription fac-
tor proteins. Alignments of the homeodo-
main primary amino acid sequence are 
shown. Dashes denote gaps introduced to 
optimize alignments; dots denote amino 
acid identity at that position; the box shows 
the equivalent amino acids for T194.
 d Generation of radiolabeled WT and 
T194R LHX3 proteins from cDNA expres-
sion vectors by in vitro transcription/trans-
lation using rabbit reticulocyte lysates in 
the presence of  35 S-methionine. Labeled 
products were separated by SDS electro-
phoresis and dried gels were visualized by 
fluorography. The migration positions of 
protein standards (in kDa) are shown. Con-
trol = Reaction from a lysate programmed 
with empty vector (negative control). 
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main, we first made a bioinformatic structural prediction 
using the LHX3 homeodomain amino acid sequence. A 
model predicting LHX3 interaction with target DNA was 
performed, using the engrailed homeodomain/DNA com-
plex structure  [22] as a template. The LHX3 homeo domain 
is composed of three predicted   -helix motifs in a helix-
turn-helix structure ( fig. 3 a). In the 3D model predicted for 
the WT protein, T194 is located at the end of the second 
  -helix (green in  fig. 3 ), and it contributes to stabilize the 
tertiary structure of the homeodomain by establishing a 
predicted hydrogen bond with a glutamine (Q170) residue 
located at the beginning of the first   -helix ( fig. 3 b). When 
T194 is mutated to arginine, the hydrogen bond with the 
glutamine 170 amino acid is maintained. However, from 
the 26 possible predicted rotamer structures for an argi-
nine residue at position 194 (194R), 25 predictions result in 
steric hindrances, mainly with Q170 and a nearby leucine 
(L172) ( fig. 3 c, d), suggesting that these steric hindrances 
may destabilize the helix-turn-helix tertiary structure, 
thereby reducing DNA-binding and gene activation.
 DNA-Binding Properties of T194R LHX3 
 To test DNA binding, WT and T194R LHX3 proteins 
were generated in vitro and DNA binding was studied by 
EMSA analysis using radiolabeled LHX3-binding sites. 
Whereas WT LHX3 bound to probes representing the 
LHX3 consensus-binding site  [23] or the   GSU promoter 
pituitary glycoprotein-binding element, T194R LHX3 
did not interact with these sites ( fig. 4 a, b).
 T194R LHX3 Does Not Activate Tested Pituitary 
Target Genes 
 To examine the ability of the T194R LHX3 protein to 
activate pituitary genes, LHX3 expression vectors were 
cotransfected with a   GSU promoter reporter gene into 
pituitary GHFT1 cells. WT LHX3a activated the   GSU 
promoter, while T194R LHX3 did not ( fig. 5 a). To test a 
different type of pituitary promoter, the  prolactin  (P RL) 
promoter/enhancer also was investigated. LHX3 alone is 
a moderate activator of  PRL transcription, but in combi-
nation with the PIT-1 pituitary transcription factor, the 
Homeodomain interaction with target DNA
WT (Thr194) Mutant (Arg194; rotamer 1) Mutant (Arg194; rotamer 2)
a
b c d
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 Fig. 3. Structural prediction of LHX3 ho-
meodomain/DNA interaction. A model of 
LHX3 interaction with target DNA was 
performed using the engrailed homeodo-
main/DNA complex as a template  [22] .
 a Ribbon model of WT LHX3 homeodo-
main/DNA showing the three   -helices in 
orange (helix 1), green (helix 2) and purple 
(helix 3).  b Predicted WT LHX3 homeo-
domain with a threonine at position 194 
(Thr194).  c ,  d Predicted T194R LHX3 ho-
meodomain with an arginine at position 
194 (Arg194). Twenty-six different rotam-
ers for this residue are possible. In all cases, 
except rotamer 21, these result in steric 
hindrances with other amino acids (main-
ly with glutamine 170 [Gln170] and leucine 
172 [Leu172]). The figure shows two of the 
R194 rotamers (green side chains) that de-
stabilize the tertiary structure by causing 
steric hindrance (purple dotted lines) with 
glutamine 170 and leucine 172 (orange side 
chains). 
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effects are synergistic  [5, 7] . The GHFT1 cells contain 
some endogenous PIT-1. As for   GSU , WT LHX3 acti-
vated the  PRL reporter gene, but T194R LHX3 was inac-
tive ( fig. 5 b).
 Discussion 
 We have characterized a novel mutation (T194R) in 
the human  LHX3 transcription factor gene that is associ-
ated with a syndrome featuring CPHD (GH, PRL, FSH, 
LH deficiency and later onset of ACTH deficiency), lim-
ited neck rotation, pituitary structural defects including 
a hypoplastic anterior lobe and a cystic structure within 
the anterior sella, respiratory distress, and sensorineural 
hearing loss. In addition, patient IV2 had cardiac defects 
including a patent ductus artery and an atrial septal de-
fect. It is hard to determine whether these cardiac prob-
lems are associated with the T194R  LHX3 mutation; or 
because the parents are distantly related, the cardiac de-
fects could represent a second genetic defect. The obser-
vation of cystic structure within the anterior part of the 
sella is a new finding for  LHX3 patients but may be re-
lated to other observations of uncharacterized pituitary 
masses in  LHX3 patients [e.g.  13, 15 ].
 LHX3 gene mutations are comparatively rare  [17] , and 
their phenotypic outcomes are likely dependent on sev-
eral parameters including the nature of the result of the 
mutation and the genetic background of the affected fam-
ilies. The family described in this report has several re-
ported cases of infant deaths (patients II4, III6, III7 in  fig. 
1 a), suggesting that if these patients carried homozygous 
T194R mutations, in the absence of successful medical 
intervention, the T194R mutation is a relatively severe 
mutation that can be lethal without patient treatment. 
Perinatal mortality has been reported in other families 
with  LHX3 gene mutations that are predicted to disable 
protein function [e.g.  13, 17 ].
a b
 Fig. 4. The LHX3 T194R protein does not bind to LHX3 DNA 
recognition elements. EMSA experiments were performed using 
the WT or T194R LHX3 proteins translated in vitro in rabbit re-
ticulocyte lysates and radiolabeled probes representing the LHX3 
consensus-binding site  [23] ( a ) or the   GSU promoter pituitary 
glycoprotein-binding element ( b ). Unprogrammed lysates were 
used as negative controls (Control). The LHX3/DNA complexes 
are denoted by arrowheads. F = Free probe. 
a b
 Fig. 5. The LHX3 T194R protein is unable to activate pituitary 
target genes.  a Expression vectors for WT and T194R LHX3 pro-
teins were transiently cotransfected into mouse pituitary GHFT1 
cells with a  luciferase reporter gene under the control of the   GSU 
promoter. Promoter activity was assayed by measuring luciferase 
activity 48 h after transfection. Negative controls (Control) re-
ceived equivalent amounts of empty expression vector plasmid. 
Activities are mean (light units/10 s/  g total protein) of triplicate 
assays  8 SEM. A representative experiment of at least three ex-
periments is depicted.  b Similar experiments to those depicted in 
 a were performed using a  prolactin (PRL) promoter/enhancer re-
porter gene. 
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 Respiratory distress was observed in both patients 
characterized with  LHX3 T194R mutations. This has 
been seen before with some  LHX3 patients  [14] . Muta-
tions in genes encoding other pituitary transcription fac-
tors such as LHX4 and PROP1 have been shown to cause 
defects in lung development and respiratory distress syn-
drome symptoms in mouse models  [25, 26] and in human 
patients with  PIT-1 gene mutations [e.g.  27 ]. In a mouse 
PROP1 deficiency model, pituitary hormone deficiencies 
(especially perhaps the thyroid axis hormones) lead to 
lower levels of the NKX2.1/TITF1 transcription factor, 
atelectasis of the lungs, and reduced lung surfactant, re-
sulting in respiratory distress syndrome  [26] . Interesting-
ly, these phenotypes vary significantly depending on the 
genetic background  [26] . In the patients described here, 
the genetic background may perhaps have promoted or 
exacerbated the respiratory distress associated with the 
 LHX3 mutation.
 The index patient (IV4) described here initially pre-
sented with a deficiency of all anterior pituitary hor-
mones except ACTH. However, within about 1 year, 
ACTH deficiency developed. Some other forms of  LHX3 
mutations have also been associated with ACTH defi-
ciencies, whereas others have not  [13–18] . It is clear there-
fore that patients with  LHX3 -associated CPHD should be 
monitored for evolving ACTH axis deficiencies during 
childhood and as adults, as have been similarly described 
for mutations in the gene encoding the PROP1 homeodo-
main transcription factor [e.g.  28 ].
 The striking conservation of the threonine at posi-
tion 194 in human LHX3a in all known LHX3/LIM3 
proteins and in other human LIM-HD factors ( fig.  2 ) 
suggests that it is critical to the function of LIM-HD 
class transcription factors. Indeed, it is part of the amino 
acid sequence ‘signature’ that defines the LIM subclass 
of homeodomain proteins  [29] . This residue is predicted 
to lie at the end of the second helix of the homeodomain 
and the equivalent amino acid in many other homeodo-
mains is often also a threonine (e.g. in PITX2, PROP1, 
PAX4) or an isoleucine or leucine residue (e.g. in POU 
factors such as PIT1/POU1F1, in NK class homeodo-
mains, and in many of the HOX proteins)  [29] . Intrigu-
ingly, several homeodomain proteins have been experi-
mentally altered at this equivalent position (e.g. by 
changing a leucine to a proline) to generate non-DNA-
binding derivatives that can act as dominant negative 
Table 2. R ecessive mutations in the human LHX3 gene causing CPHD
p.Y111C
(Netchine et al. [16], 
Rajab et al. [18])
23-bp deletion
(Netchine et al. [16], 
Rajab et al. [18])
g.159delT
(Bhangoo et al. [13])
p.A210V
(Pfäffle et al. [17])
p.E173Ter
(Pfäffle et al. [17])
p.W224Ter
(Pfäffle et al. [17])
Hormone
deficiencies
reported
GH, TSH,
PRL, LH, FSH
GH, TSH, 
PRL, LH, FSH
GH, TSH, 
PRL, LH, FSH
GH, TSH, 
PRL, LH, FSH 
(ACTH sometimes low)
GH, TSH, 
PRL, LH, FSH 
(ACTH low)
GH, TSH,
PRL, LH, FSH
Anterior
pituitary 
morphology
Hypoplastic Enlarged Hypointense
pituitary
lesion
Enlarged Hypoplastic Normal
Neck rotation Limited Limited Limited Limited Limited Normal
Hearing 
deficiencies
Moderate to mild
sensorineural
hearing defect
Completely
deaf
Not reported Not reported Not reported Not reported
Mental/
learning
deficiencies
Not reported Extreme mental 
retardation
Some mental
retardation
Not reported Not reported Not reported
Location of
mutation
Missense mutation 
within exon 3
Deletion affecting 
exon 3 and splice-
donor site
Deletion
in exon 2
Missense mutation
in exon 5
Complex mutation 
in exon 3
Nonsense mutation 
in exon 5
Protein
domain(s)
affected
Second LIM domain Multiple Multiple HD Multiple Loss of carboxyl 
terminus
Protein domains: Multiple = multiple domains affected or deleted resulting in an inactivated gene function; HD = homeodomain.
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proteins in overexpression experiments to probe the role 
of the endogenous homeodomain factor. Such approach-
es have been especially pursued with other developmen-
tal proteins such as NKX2.5 and MIX1  [30, 31] . In these 
experiments, it is thought that overexpression of the al-
tered protein can titrate essential cofactor proteins away 
from the endogenous factor and thereby interfere with 
its normal activity. In the case of the patients described 
in this report, it appears that the T194R LHX3 protein 
has lost DNA-binding ability, consistent with observa-
tions of alteration of this position in other homeodo-
main proteins such as MIX1  [31] . However, the ‘T194R’ 
mutation in  LHX3 appears to act in a simple recessive 
fashion, rather than in a dominant negative mode, with 
heterozygous individuals in the family not demonstrat-
ing affected symptoms. This is consistent with the pre-
viously described phenotypes of heterozygous and ho-
mozygous  LHX3 patients and experimental  Lhx3 model 
animals.
 This report describes the first example of a missense 
mutation in exon IV of the  LHX3 gene. The alteration of 
an essential amino acid in the DNA-binding domain 
provides a clear example of structure/function conse-
quences of  LHX3 mutations. To date, a range of muta-
tions affecting the  LHX3 gene and its encoded protein 
have been described ( table 2 ). These include deletions 
that remove all or most of the gene, splice site mutations 
that are predicted to block gene function, missense point 
mutations that cause critical amino acid substitutions, 
or nonsense mutations that cause inactivating trunca-
tions of the protein, and nonsense mutations that result 
in loss of the carboxyl terminus (W224Ter)  [13–18] . Mu-
tations that impact the overall function of the gene or 
protein appear to result in diseases affecting both pitu-
itary gland development and physiology and the ner-
vous systems (causing limited neck rotation, deafness, 
developmental delay, etc.). The T194R mutation de-
scribed here falls into this class. Similarly, the A210V 
missense mutation apparently also results in an inactive 
LHX3 protein; however, unlike the T194R form, this 
substitution does retain some slight DNA-binding func-
tion  [17] . The A210V patients were not all described to 
have ACTH axis deficiencies  [17] , but whether this re-
flects the nature of the mutation or an influence of ge-
netic background is unclear. These phenotypes suggest 
that the LIM domains and homeodomain are required 
LHX3
gene deletion
(Pfäffle et al. [17])
p.K50Ter
(Rajab et al. [18])
Intragenic deletion
of 3,088 bp
(Rajab et al. [18])
A]G splice mutation
in intron 3
(Kristrom et al. [15])
p.R77Ter
(Bonfig et al. [14])
p.T194R
(this study)
GH, TSH,
PRL, LH, FSH
GH, TSH, 
PRL, LH, FSH,
ACTH
GH, TSH, 
PRL, LH, FSH,
ACTH
GH, TSH, 
PRL, LH, FSH, 
ACTH
GH, TSH, 
PRL, LH, FSH,
ACTH
GH, TSH,
PRL, LH, FSH,
ACTH
Severely
hypoplastic/
aplastic
Hypoplastic Hypoplastic Aplastic/hypoplastic
(sometimes cysts)
Hypoplastic Hypoplastic
(possible cyst)
Limited Limited Limited Limited Limited Limited
Not reported Sensorineural
deafness
Sensorineural
hearing defect
Sensorineural
hearing defect
Sensorineural
hearing defect
Sensorineural
hearing defect
Psychomotor
development is
severely retarded
Not reported Some learning 
difficulties
Not reported Not reported Not reported
Complete gene 
deletion
Nonsense 
mutation
in exon 2
Deletion of 
exons 2–5
A]G splice acceptor
mutation
in intron 3
Nonsense
mutation
in exon 2
Missense
mutation
in exon 4
Multiple Multiple Multiple Multiple Multiple HD
 Bechtold-Dalla Pozza  /Hiedl  /Roeb  /
Lohse  /Malik  /Park  /Durán-Prado  /Rhodes  
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for all LHX3 functions. However, the carboxyl terminus 
of LHX3 contains an activation domain that is required 
for pituitary gene activation  [32] , and patients and 
mouse models of CPHD with mutations causing spe-
cific loss of the carboxyl terminus of the LHX3 protein 
have pituitary disease but not the limited neck rotation 
or other nervous system symptoms, demonstrating that 
the roles in the pituitary and nervous system are mo-
lecularly separable  [12, 17] .
 In summary, this study expands the range of known 
molecular defects in the  LHX3 gene and extends our 
understanding of the phenotypic features and develop-
mental disease course associated with mutations in this 
gene.
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